NECITUMUMAB for Lung neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 24 adverse event reports in the FDA FAERS database where NECITUMUMAB was used for Lung neoplasm malignant.
Most Reported Side Effects for NECITUMUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Platelet count decreased | 68 | 18.5% | 6 | 26 |
| Malignant neoplasm progression | 54 | 14.7% | 19 | 16 |
| Rash | 48 | 13.1% | 4 | 14 |
| Hypomagnesaemia | 46 | 12.5% | 6 | 14 |
| Neutrophil count decreased | 45 | 12.3% | 4 | 16 |
| Dermatitis acneiform | 44 | 12.0% | 5 | 12 |
| Febrile neutropenia | 30 | 8.2% | 3 | 12 |
| Decreased appetite | 29 | 7.9% | 5 | 6 |
| Neutropenia | 26 | 7.1% | 2 | 7 |
| Nausea | 21 | 5.7% | 6 | 10 |
| Death | 20 | 5.5% | 20 | 1 |
| Anaemia | 19 | 5.2% | 1 | 10 |
| Pneumonia | 19 | 5.2% | 3 | 11 |
| White blood cell count decreased | 18 | 4.9% | 2 | 7 |
| Skin disorder | 17 | 4.6% | 2 | 6 |
Other Indications for NECITUMUMAB
Squamous cell carcinoma of lung (122)
Non-small cell lung cancer (52)
Product used for unknown indication (43)
Lung squamous cell carcinoma stage iv (32)
Non-small cell lung cancer stage iv (25)
Lung squamous cell carcinoma stage iii (16)
Lung squamous cell carcinoma recurrent (11)
Squamous cell carcinoma (10)
Lung cancer metastatic (5)
Lung squamous cell carcinoma metastatic (5)
Other Drugs Used for Lung neoplasm malignant
ERLOTINIB (9,207)
OSIMERTINIB (4,754)
NIVOLUMAB (4,197)
PEMBROLIZUMAB (3,575)
CARBOPLATIN (3,487)
ALECTINIB (2,932)
PEMETREXED (2,422)
CRIZOTINIB (1,949)
BEVACIZUMAB (1,810)
PACLITAXEL (1,747)